KURAKura Oncology, Inc.
What is the market doing?
No clear lean: nothing decisive, though a crowded short (+16% of shares).
Rangebound, no clear trend. Price is −2% vs its 200-day average.
A crowded short, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How KURA is trading
Kura Oncology, Inc. is +3.5% over the past year while the S&P 500 is +16%: 13 points behind the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −1.8%
vs 200-day average · below trend, but not far
- RSI (14)
- 35
RSI (14) · neutral
- Below its 52-week high
- 29%
Below its 52-week high
Details›
- Last close2026-10-23
- $9.61
- 1 monthS&P 500 −0.94%
- −12%
- 1 yearS&P 500 +16%
- +3.5%
- 5 yearsS&P 500 +86%
- −47%
- vs 50-day average$11.30
- −15%
- 52-week high
- $13.59
- 52-week low
- $7.40
- Annualised volatility
- 63%
| Year | Return |
|---|---|
| 2026 (year to date) | −7.6% |
| 2025 | +19% |
| 2024 | −39% |
| 2023 | +16% |
| 2022 | −11% |
| 2021 | −57% |
| 2020 | +138% |
| 2019 | −2.1% |
| 2018 | −8.2% |
| 2017 | +159% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 6 of 10 | +4.5% |
| Feb | 10 | 6 of 10 | +5.0% |
| Mar | 10 | 6 of 10 | −3.6% |
| Apr | 10 | 3 of 10 | −0.45% |
| May | 10 | 6 of 10 | +4.1% |
| Jun | 10 | 6 of 10 | +5.4% |
| Jul | 11 | 5 of 11 | +1.8% |
| Aug | 11 | 6 of 11 | +9.7% |
| Sep | 11 | 5 of 11 | +9.6% |
| Oct | 11 | 3 of 11 | −7.9% |
| Nov | 10 | 8 of 10 | +5.2% |
| Dec | 10 | 4 of 10 | −0.41% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.
Biotechnology
Ranks #101 of 194 by RyuScore